Clinical data | |
---|---|
Pronunciation | /mɛθəˈkweɪloʊn/ |
Trade names | Bon-Sonnil, Dormogen, Dormutil, Mequin, Mozambin, Pro Dorm, Quaalude, Somnotropon, Torinal, Tuazolona Methaqualone hydrochloride: Cateudyl, Dormir, Hyptor, Melsed, Melsedin, Mequelon, Methasedil, Nobadorm, Normorest, Noxybel, Optimil, Optinoxan, Pallidan, Parest, Parmilene, Pexaqualone, Renoval, Riporest, Sedalone, Somberol, Somnifac, Somnium, Sopor, Sovelin, Soverin, Sovinal, Toquilone, Toraflon, Tualone, Tuazol |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 70–80% |
Elimination half-life | Biphasic (10–40; 20–60 hours) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.710 |
Chemical and physical data | |
Formula | C16H14N2O |
Molar mass | 250.301 g·mol−1 |
3D model (JSmol) | |
Melting point | 113 °C (235 °F) |
| |
| |
(verify) |
Methaqualone is a hypnotic sedative. It was sold under the brand names Quaalude (/ˈkweɪluːd/ KWAY-lood) and Sopor among others, which contained 300 mg of methaqualone, and sold as a combination drug under the brand name Mandrax, which contained 250 mg methaqualone and 25 mg diphenhydramine within the same tablet, mostly in Europe. Commercial production of methaqualone was halted in the mid-1980s due to widespread abuse and addictiveness. It is a member of the quinazolinone class.